Introduction

88
The succinate dehydrogenase (SDH) enzyme is composed of four subunits (A-D) and has a 89 key role in the Krebs cycle and oxidative phosphorylation 6 . In the past two decades germline 90 mutations in the genes encoding the four SDH subunits (SDHA/SDHB/SDHC/SDHD), 91 collectively known as SDHx have emerged as an important cause of human neoplasia and a 92 paradigm for the role of disordered cellular metabolism in oncogenesis [1] [2] [3] [4] [5] 7 . SDHx mutations with SDH-deficient wtGIST achieve disease stabilisation with imatinib therapy 12 LCModel reports both peak area and the estimated uncertainty in fitting of the peak (%SD).
145
This uncertainty measure was used to stratify the results using the following algorithm: 1) if
146
%SD of choline was >15%, the spectrum was discarded as a technical failure, because it was 147 assumed that choline should be detectable in a metabolically active tumour, such that 148 SD>15% would indicate probable data quality issues; 2) succinate detection was taken as 149 positive if its %SD was <50%, and negative if it was >50%. The succinate to choline ratio 150 was quantified (SCR), the full width at half maximum height (FWHM) of the water peak in
151
Hz was measured in SAGE and recorded as an additional data quality metric, and an expert 152 spectroscopist was asked to rate whether detected succinate peaks were convincing or 153 unconvincing based on data displayed both in LCModel and in SAGE. 
Results
161
Patients and clinical phenotype 162 Fifteen subjects (6 females, 9 males; mean age 40 years (range 21-80 years) were studied.
163
Seven wtGIST, three unilateral adrenal phaeochromocytomas, three abdominal PGL's, a 164 large left glomus PGL and a non-functioning pituitary macroadenoma were examined. Nine 165 patients (60%) had metastatic disease: six with wtGIST, two with an abdominal 166 paraganglioma and one with a unilateral phaeochromocytoma. The liver was the most 167 common site for metastases (7/9, 77.7%). Three patients had multicentric primary tumours,
168
including subject #5 who presented with a metastatic wtGIST and was subsequently 169 diagnosed with a 1.9 cm carotid body PGL (figure 2d, case 5), subject #9 with an abdominal 170 paraganglioma and a small left sided 1.5 cm carotid paraganglioma (figure 3b, case 9), and 171 subject #8 with a large left sided glomus paraganglioma and a 2 cm prolactin secreting 172 pituitary adenoma (figure S1, case 8). Only two patients had a positive family history, (Table   173 1: case 2 and case 6).
174
Genotype
175
A germline mutation in a SDHx gene was identified in 9/15 (60%) of subjects: 5 in SDHB (4 176 missense variants and 1 truncating variant) and 4 in SDHA (1 missense and 3 truncating).
177
Two further patients were diagnosed with a somatic SDHC epimutation (Table 1) .
179
H-MRS succinate analysis
180
The 1 H-MRS characteristics of the 15 patients are shown in Supplementary Table S1 . The 181 mean size of the tumour selected for spectra acquisition was 5.5 cm (median: 3.3 cm, range: 182 1.8-12 cm). The liver was the most common site to be assessed (n = 6), but good quality 183 9 spectra were also obtained from the pituitary (n = 1), and PPGL tumours (n = 5). The subjects 184 were divided into four groups according to whether a succinate tumour peak was: present, 185 absent, a borderline peak was detected, or technical failure prevented interpretation of the 186 spectra.
188
Succinate peak detected 189 Succinate was detected at 2.4 ppm in 6 patients (50 %). The mean SCR in these patients was Table S1 ). Figures 5a, 5b) .
234
Following four cycles of treatment, a repeat 1 H-MRS examination on the same pelvic nodal 235 metastases revealed a choline peak but no succinate peak (Figure 5c ). Though the MRI 236 imaging features of the metastatic lesions were unchanged pre-and post-treatment, the loss of 
respectively, Figures 2f-g).
249
Repeatability of 1 H-MRS was evaluated in two patients by investigating different tumour 250 deposits during the same study examination (case#5) and the same tumour deposit twice was detected in all 5 with an SDHx mutation but not in the 4 patients without a mutation 16 .
263
We have demonstrated for the first time that 1 H-MRS can also be used to determine the SDH 264 status of GISTs and pituitary adenomas and that a succinate peak can be detected in SDH- lowering the overall succinate levels in large tumours, and therefore suggests that the method 283 is measuring real differences in succinate, which are independent of tumour size. However,
284
we recommend using a size threshold of greater than 2 cm where possible to improve the 285 sensitivity of the test.
286
There is increasing interest in understanding the metabolic adaptations that occur during 287 tumorigenesis and how these might be exploited for novel therapeutic interventions.
288
Increased production of lactate during aerobic glycolysis in most cancers, or the Warburg spectral quality was poor in close proximity to metal dental work, adjacent to air spaces 323 including the lung, in bone metastases, and was susceptible to motion artefact. In this study, 324 the technical failure rate was 26%, which is similar to the failure rate reported in previous 325 studies using 1 H-MRS 16 . Importantly, no cases was excluded from this prospective study, the number of scan averages in our study during spectral acquisition was less than half those 335 reported in a previous study 16 showing a broad unreliable peak at 2.4 ppm, which was not convincing for succinate. 
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